Primary cardiac angiosarcoma in a 25-year-old man: excision, adjuvant chemotherapy, and multikinase inhibitor therapy

Tex Heart Inst J. 2013;40(2):186-8.

Abstract

Primary cardiac tumors do not occur frequently, and only one quarter of them, chiefly sarcomas, are malignant. Patients with angiosarcoma typically have a shorter survival time than do patients with other sarcomas, and the prognosis for survival depends strictly on the stage of the disease at the time of diagnosis and the possibility of complete surgical excision. Chemotherapy and radiotherapy have well-established postoperative roles because of the high probability of metastasis. We report the case of a 25-year-old man who presented with pericardial effusion and echocardiographic evidence of an intracavitary right atrial mass but without the bulky, infiltrative growth typical of this location of the disease. Malignancy was suggested by the clinical presentation, the location of the mass in the right side of the heart, and the absence of conditions favoring thrombus formation. After complete surgical excision, the mass was confirmed to be an angiosarcoma. Conventional adjuvant chemotherapy and maintenance therapy with inhibitors of CD117 (c-kit) and vascular endothelial growth factor relieved the patient's clinical symptoms and enabled his long-term, disease-free survival. In addition to reporting this case, we discuss aspects of the diagnosis and treatment of angiosarcoma.

Keywords: Antineoplastic combined chemotherapy protocols/therapeutic use; chemotherapy, adjuvant; disease-free survival; heart neoplasms/drug therapy/epidemiology/surgery; prognosis; sarcoma/surgery/therapy; treatment outcome.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Benzamides / therapeutic use*
  • Biopsy
  • Cardiac Surgical Procedures*
  • Chemotherapy, Adjuvant
  • Echocardiography, Transesophageal
  • Heart Neoplasms / enzymology
  • Heart Neoplasms / pathology
  • Heart Neoplasms / therapy*
  • Hemangiosarcoma / enzymology
  • Hemangiosarcoma / pathology
  • Hemangiosarcoma / therapy*
  • Humans
  • Imatinib Mesylate
  • Male
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-kit / antagonists & inhibitors
  • Proto-Oncogene Proteins c-kit / metabolism
  • Pyrimidines / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Imatinib Mesylate
  • Proto-Oncogene Proteins c-kit